What's Going With Dialysis Firm DaVita Stock On Friday? - DaVita ( NYSE:DVA )
Ransomware breach exposed 2.7 million DaVita patients' personal and health data. DaVita Q2 EPS of $2.95 beats $2.79 estimate; $2 billion share buyback approved. The market is reacting to Powell's speech. Learn how to time your next move. Details here →
2 Warren Buffett Stocks to Buy Hand Over Fist and 1 to Avoid
The Oracle of Omaha's investing strategies have stood the test of time.
Rockwell Medical RMTI Q2 2025 Earnings Transcript
Image source: The Motley Fool.Thursday, August 14, 2025 at 8 a.m. ETPresident and Chief Executive Officer - Mark StrobeckContinue reading ...
Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Rockwell Medical Tops Q2 EPS View
Rockwell Medical ( NASDAQ:RMTI ) , a key supplier of hemodialysis concentrates, released its second quarter 2025 earnings on August 14, 2025. The most notable development was a steep year-over-year revenue decline of 38% as the company absorbed the financial impact of its largest customer's ...
Here's Why DaVita HealthCare ( DVA ) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Are Investors Undervaluing DaVita ( DVA ) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
3 No-Brainer Warren Buffett Stocks to Buy Right Now
The Oracle of Omaha's approach to picking stocks still works as well as it ever has.
Akebia ( AKBA ) Q2 Revenue Jumps 43%
Akebia Therapeutics ( NASDAQ:AKBA ) , a biopharmaceutical company specializing in kidney disease treatments, reported its earnings on August 7, 2025, covering results for the quarter. The headline news was a marked upturn in revenue and a transition to positive GAAP net income.
DaVita Stock Down Despite Q2 Earnings Beat, Gross Margin Expands
DVA reports strong second-quarter 2025 results with earnings and revenue beat, along with a boost in gross margin, driven by core operations.
DaVita HealthCare ( DVA ) Q2 Earnings and Revenues Top Estimates
DaVita HealthCare (DVA) delivered earnings and revenue surprises of +9.26% and +1.31%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Warren Buffett Just Bought Even More of This Dirt-Cheap Stock
Berkshire Hathaway now owns 37% of this company.
Encompass Health ( EHC ) Q2 Earnings and Revenues Surpass Estimates
Encompass Health (EHC) delivered earnings and revenue surprises of +16.67% and +2.29%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Akebia Initiates Vafseo® ( vadadustat ) Post-Marketing Study in Conjunction with Large Dialysis Organization - Akebia Therapeutics ( NASDAQ:AKBA )
CAMBRIDGE, Mass., Aug. 04, 2025 ( GLOBE NEWSWIRE ) -- Akebia Therapeutics®, Inc. AKBA, a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the initiation of a post-marketing study to identify additional potential benefits of ...
DaVita HealthCare ( DVA ) Registers a Bigger Fall Than the Market: Important Facts to Note
DaVita HealthCare (DVA) closed the most recent trading day at $140.37, moving 2.91% from the previous trading session.
Can Phosphate Binders Drive DaVita Stock Before Q2 Earnings?
DVA rides early momentum from phosphate binders ahead of second-quarter 2025 earnings, but PD supply issues may cloud growth.
Vystar Introduces New RxAir-800 Replacement Cartridge Extended Life UV-C Bulb
New RxAir400 Pro UV-C bulb replacement cartridge provides 18,000 vs 9,000 hr. use.
Chemed ( CHE ) Q2 Earnings Miss Estimates
Chemed (CHE) delivered earnings and revenue surprises of -10.67% and +0.45%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
DaVita HealthCare ( DVA ) Reports Next Week: Wall Street Expects Earnings Growth
DaVita HealthCare (DVA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Universal Health to Report Q2 Earnings: What Do the Key Estimates Say?
UHS' Q2 results are likely to reflect gains from hospital and behavioral health services. However, rising costs may cloud earnings upside.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Want Better Returns? Don't Ignore These 2 Medical Stocks Set to Beat Earnings
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Quest Diagnostics ( DGX ) Beats Q2 Earnings and Revenue Estimates
Quest Diagnostics (DGX) delivered earnings and revenue surprises of +1.95% and +1.54%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
DaVita HealthCare ( DVA ) Stock Sinks As Market Gains: What You Should Know
DaVita HealthCare (DVA) reached $139.43 at the closing of the latest trading day, reflecting a -1.23% change compared to its last close.
Will DaVita HealthCare ( DVA ) Beat Estimates Again in Its Next Earnings Report?
DaVita HealthCare (DVA) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
HCA Healthcare to Report Q2 Earnings: Key Estimates to Note
The Zacks Consensus Estimate for HCA's Q2 EPS and revenues suggests a year-over-year upside despite higher costs and surgery volume pressure.
DaVita HealthCare ( DVA ) Dips More Than Broader Market: What You Should Know
In the closing of the recent trading day, DaVita HealthCare (DVA) stood at $140.53, denoting a -2.01% move from the preceding trading day.
Reasons to Add Fresenius Medical Stock to Your Portfolio Now
FMS continues to gain traction on the back of acquisitions & partnerships. A tough regulatory environment raises concerns.
Here's Why DaVita HealthCare ( DVA ) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
DaVita HealthCare ( DVA ) Stock Sinks As Market Gains: Here's Why
DaVita HealthCare (DVA) concluded the recent trading session at $141.84, signifying a -1.36% move from its prior day's close.
Zacks Industry Outlook Highlights Quest Diagnostics, Encompass Health, DaVita and The Pennant
DGX, EHC, DVA, and PNTG are riding the outpatient healthcare shift as tech, AI, and aging demand reshape the care landscape.
4 Stocks to Watch in a Rapidly Shifting Outpatient Home Health Space
An aging global population and AI dominance are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry despite the macroeconomic challenges. DGX, EHC, DVA and PNTG are well-poised to gain.
DaVita HealthCare ( DVA ) Rises As Market Takes a Dip: Key Facts
In the closing of the recent trading day, DaVita HealthCare (DVA) stood at $146.71, denoting a +2.99% move from the preceding trading day.
FMS Stock Likely to Gain on New Optimization Plan FME Reignite
Fresenius Medical Care unveils FME Reignite, targeting one billion euros in cost savings, tech upgrades and enhanced shareholder returns.
DaVita HealthCare ( DVA ) Outperforms Broader Market: What You Need to Know
DaVita HealthCare (DVA) reached $137.84 at the closing of the latest trading day, reflecting a +1.26% change compared to its last close.
Reasons to Add Fresenius Medical Stock to Your Portfolio Now
FMS continues to gain traction on the back of acquisitions & partnerships. A tough regulatory environment raises concerns.
Buffett Bought More of This High-Yield Dividend Stock in Q1. Should You Buy It, Too?
Just because Warren Buffett is wary of the stock market right now doesn't mean he isn't buying any stocks. In the first quarter of 2025, the legendary investor added to Berkshire Hathaway's stakes in 12 stocks and initiated a new position in another.The list included a high-yield dividend stock ...
Made in the USA: Warren Buffett Sells Out of 1 International Stock and Doubles His Stake in 2 U.S. Companies
Investors eagerly anticipate the Berkshire Hathaway quarterly 13F filings, which detail the company's current equity holdings. It provides investing inspiration for individual investors, but more than that, it's a window into what Chief Executives Officer Warren Buffett might be thinking about ...
Warren Buffett Just Sold These 8 Stocks, One of Which Remains a Phenomenal Bargain ( and a Top Holding of Mine )
The Oracle of Omaha has been a big-time seller of stocks for 10 consecutive quarters -- but there's one sale he may regret.
DaVita Stock Down Despite Q1 Earnings Beat, Margins Contract
Strength in revenue per treatment and dialysis patient service revenues drives DVA's first-quarter 2025 performance despite a year-over-year decline in normalized non-acquired treatment.
DaVita HealthCare ( DVA ) Q1 Earnings and Revenues Beat Estimates
DaVita HealthCare (DVA) delivered earnings and revenue surprises of 14.29% and 0.38%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
US Stock Futures Rise As US, China Agree To 90-Day Tariff Pause: 'Wider Earnings Growth Should Drive More Balanced Market Performance,' Says Expert - Alibaba Gr Hldgs ( NYSE:BABA ) , Baidu ( NASDAQ:BIDU )
U.S. stock futures jumped on Monday after a muted day of trade on Friday. Futures of major benchmark indices were trading over 2% in premarket. U.S. and China announced a 90-day truce to pause the reciprocal tariffs on Monday and revised it from 125% to 10%.
Dow Falls Over 100 Points, Also Records Weekly Loss: Fear & Greed Index Remains In 'Greed' Zone - DaVita ( NYSE:DVA ) , Fox ( NASDAQ:FOX )
The CNN Money Fear and Greed index showed almost no change in the overall market sentiment, while the index remained in the "Greed" zone on Friday. U.S. stocks settled lower on Friday, with the Dow Jones index falling more than 100 during the session ahead of trade talks between the US and ...
Fox, NRG Energy And 3 Stocks To Watch Heading Into Monday - DaVita ( NYSE:DVA ) , Fox ( NASDAQ:FOX )
With U.S. stock futures trading higher this morning on Monday, some of the stocks that may grab investor focus today are as follows: Wall Street expects Fox Corporation FOX to report quarterly earnings at 91 cents per share on revenue of $4.18 billion before the opening bell, according to data ...
Dow Futures Rally Over 400 Points As US, China 'Come To Agreement' In Geneva Trade Talks - Monday.Com ( NASDAQ:MNDY ) , DaVita ( NYSE:DVA )
U.S. stock futures rose Sunday evening after weekend trade talks in Geneva signaled potential de-escalation in the ongoing trade war with China. The S&P 500 Futures are up 1.35%, trading at 5,754.50, Nasdaq Futures are trading at 20,515.25, up 1.88%, and finally Dow Jones Futures are up 1.01%, ...
Vystar Develops Revolutionary Leap in Air Purification Utilizing its Patented Hughes Reactor
Boston, MA, May 09, 2025 ( GLOBE NEWSWIRE ) -- Vystar® Corporation ( OTCQB: VYST ) Vystar has completed what it believes to be a revolutionary, next-generation RXAIR prototype using the new Fluid Energy Conversion - Hughes Reactor. The Hughes Reactor was developed by Dr. Bryan Stone, a Vystar ...
Astrana Health, Inc. ( ASTH ) Q1 Earnings and Revenues Lag Estimates
Astrana Health, Inc. (ASTH) delivered earnings and revenue surprises of -39.13% and 2.33%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Can Revenue Cycle Operations Drive DVA Stock Before Q1 Earnings?
Continued strength in revenue cycle operations is likely to have boosted DaVita's top line in the first quarter despite supply challenges weighing on its performance.
DaVita HealthCare ( DVA ) Outperforms Broader Market: What You Need to Know
DaVita HealthCare (DVA) closed the most recent trading day at $143.96, moving +0.94% from the previous trading session.
LifeStance Health Group ( LFST ) Reports Break-Even Earnings for Q1
LifeStance Health (LFST) delivered earnings and revenue surprises of 100% and 0.08%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
